{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=6",
    "query": {
      "condition": "Normal Subjects",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 2506,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T21:14:05.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00543075",
      "title": "Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Renal Function",
        "Mildly Impaired Renal Function",
        "Moderately Impaired Renal Function"
      ],
      "interventions": [
        {
          "name": "Genasense (oblimersen, G3139)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genta Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Weeks and older"
      },
      "enrollment_count": 23,
      "start_date": "2006-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-13",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00543075"
    },
    {
      "nct_id": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Gastric Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Cutaneous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "SEA-TGT",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2020-05-29",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04254107"
    },
    {
      "nct_id": "NCT01871402",
      "title": "A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "000-0551 Lotion",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2013-05",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-13",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 10,
      "location_summary": "Fremont, California • San Diego, California • Arlington Heights, Illinois + 7 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871402"
    },
    {
      "nct_id": "NCT02108639",
      "title": "To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "DCV 3DAA FDC",
          "type": "DRUG"
        },
        {
          "name": "BMS-791325",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2014-04",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-10",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02108639"
    },
    {
      "nct_id": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tyrosinase/gp100/MART-1 Peptides",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 77,
      "start_date": "2004-05-31",
      "completion_date": "2009-10-31",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084656"
    },
    {
      "nct_id": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Part A/B/C/D)",
        "Non-small Cell Lung Cancer (Part E)",
        "Melanoma (Part E)",
        "Squamous Cell Cancer of the Head and Neck (Part E)",
        "Triple Negative Breast Cancer (Part F)",
        "Adrenocortical Carcinoma (Part G)",
        "Mesothelioma (Part G)",
        "High-circulating Myeloid-derived Suppressor Cells (Part H)"
      ],
      "interventions": [
        {
          "name": "IPI-549 (eganelisib)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2015-12",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637531"
    },
    {
      "nct_id": "NCT01923415",
      "title": "A Non-drug Study Profiling Cutaneous Lupus",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lupus Erythematosus, Cutaneous",
        "Lupus Erythematosus, Systemic",
        "Lupus Erythematosus, Discoid"
      ],
      "interventions": [
        {
          "name": "No intervention, skin biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "No intervention, blood collection",
          "type": "PROCEDURE"
        },
        {
          "name": "No intervention, urine collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 29,
      "start_date": "2013-04",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-09-12",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Dallas, Texas",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01923415"
    },
    {
      "nct_id": "NCT03551821",
      "title": "Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata",
        "Alopecia Totalis",
        "Alopecia Universalis"
      ],
      "interventions": [
        {
          "name": "ATI-50002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-04-11",
      "completion_date": "2018-11-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-11",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 1,
      "location_summary": "Boynton Beach, Florida",
      "locations": [
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03551821"
    },
    {
      "nct_id": "NCT04056455",
      "title": "A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Mobocertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "81 Years",
        "sex": "ALL",
        "summary": "18 Years to 81 Years"
      },
      "enrollment_count": 26,
      "start_date": "2020-03-04",
      "completion_date": "2022-04-20",
      "has_results": true,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 2,
      "location_summary": "Hialeah, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04056455"
    },
    {
      "nct_id": "NCT04990921",
      "title": "Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palliative Radiation and Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2021-09-02",
      "completion_date": "2031-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-22T21:14:05.606Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990921"
    }
  ]
}